Cannara Biotech Stock Analysis

Cannara Stock Analysis Notes

About 49.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Cannara Biotech had not issued any dividends in recent years. The entity had 1:10 split on the 13th of February 2023. Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Montreal, Canada. CANNARA BIOTECH is traded on Commodity Exchange in Exotistan. To find out more about Cannara Biotech contact Zohar Krivorot at 514 543 4200 or learn more at https://cannara.ca.

Cannara Biotech Investment Alerts

Cannara Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 159.09 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cannara Biotech's market, we take the total number of its shares issued and multiply it by Cannara Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Cannara Profitablity

The company has Profit Margin (PM) of 0.14 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.22 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.22.

Management Efficiency

Cannara Biotech has return on total asset (ROA) of 0.0655 % which means that it generated a profit of $0.0655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1544 %, meaning that it generated $0.1544 on every $100 dollars invested by stockholders. Cannara Biotech's management efficiency ratios could be used to measure how well Cannara Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.04 in 2025. Return On Capital Employed is likely to climb to 0.07 in 2025. At this time, Cannara Biotech's Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to climb to about 177.3 K in 2025, whereas Net Tangible Assets are likely to drop slightly above 50.7 M in 2025.

Technical Drivers

As of the 21st of July, Cannara Biotech shows the Risk Adjusted Performance of 0.1486, downside deviation of 3.13, and Mean Deviation of 2.37. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cannara Biotech, as well as the relationship between them. Please confirm Cannara Biotech jensen alpha, maximum drawdown, and the relationship between the information ratio and treynor ratio to decide if Cannara Biotech is priced correctly, providing market reflects its regular price of 1.74 per share.

Cannara Biotech Price Movement Analysis

Cannara Biotech Outstanding Bonds

Cannara Biotech Predictive Daily Indicators

Cannara Biotech Forecast Models

Cannara Biotech's time-series forecasting models are one of many Cannara Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cannara Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cannara Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cannara shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cannara Biotech. By using and applying Cannara Stock analysis, traders can create a robust methodology for identifying Cannara entry and exit points for their positions.

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.